InveStigAting Bladder fiELd-cycLing imAging (ISABELLA)
Research type
Research Study
Full title
InveStigAting Bladder fiELd-cycLing imAging (ISABELLA)
IRAS ID
322794
Contact name
Anne Kiltie
Contact email
Sponsor organisation
University of Aberdeen
Duration of Study in the UK
0 years, 4 months, 10 days
Research summary
Research Summary: Patients with organ-confined muscle invasive bladder cancer are treated either by removal of their bladder at cystectomy or by organ-preserving treatment, generally following neoadjuvant chemotherapy. In some cases, the neoadjuvant chemotherapy can shrink the tumour so that it is clinically undetectable but there may still be tumour cells present microscopically. This presents a difficulty during planning of radiotherapy treatments, which could then miss the tumour and lead to tumour recurrence.\n\nField-Cycling Imaging (FCI) is an emerging imaging technology pioneered at the University of Aberdeen. FCI can image human tissues non-invasively over a wide range of magnetic field strengths, directly informing on multi-scale tissue structure from nanometres to micrometres. FCI has already shown significant potential for enhanced diagnosis in a range of diseases, and recent results show several potential biomarkers of cancer in breast, colon, and brain. \n\nFCI has not been used in bladder cancer before. In this proof-of-concept study, we will recruit patients with both muscle-invasive and non-muscle invasive tumours to explore the parameters that can be obtained in bladder tumours by FCI. Summary of study results: No participants were recruited for this study.
REC name
North of Scotland Research Ethics Committee 1
REC reference
23/NS/0012
Date of REC Opinion
27 Feb 2023
REC opinion
Favourable Opinion